LAURA HALL: Open Payments
NPI 1629520937 · NORMAN, OK. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,715 in 102 payments from 16 companies in 2025. Trend: 2023 $2,471 · 2024 $2,097 · 2025 $1,715
Food & beverage: $1,715
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 25 | $425 |
| ABBVIE INC. | 33 | $346 |
| Neurocrine BioSciences, Inc. | 7 | $137 |
| Otsuka America Pharmaceutical, Inc. | 6 | $127 |
| Alkermes, Inc. | 6 | $121 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $103 |
| Teva Pharmaceuticals USA, Inc. | 4 | $93 |
| Vanda Pharmaceuticals Inc. | 3 | $83 |
| E.R. Squibb & Sons, L.L.C. | 3 | $71 |
| Axsome Therapeutics, Inc. | 3 | $61 |
Products named: CAPLYTA, VRAYLAR, INGREZZA, LYBALVI, TRINTELLIX, FANAPT, COBENFY, UZEDY.
Industry payments across OK — which companies pay providers there.
